Download PDF
Semin Neurol 2007; 27(4): 331-339
DOI: 10.1055/s-2007-985335
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Gender-Specific Challenges in the Management of Epilepsy in Women

Katherine H. Noe1
  • 1Department of Neurology, Mayo Clinic Hospital, Phoenix, Arizona
Further Information

Publication History

Publication Date:
15 August 2007 (online)

    Permissions and Reprints

ABSTRACT

The management of epilepsy in women encompasses a complex interplay between seizures, sex steroid hormones, and antiepileptic drugs (AEDs). These interactions impact every aspect of the sexual and reproductive health of women with epilepsy throughout their lifetimes. Neurologists comfortable treating seizures may feel unprepared to handle questions related to reproductive health. Several cases are provided to illustrate commonly encountered queries from women with epilepsy about catamenial epilepsy, pregnancy, breast-feeding, contraception, menopause, and bone health. Available evidence is reviewed, and guidelines for management are provided.

KEYWORDS

Antiepileptic drugs - catamenial epilepsy - teratogenesis - pregnancy - contraception

REFERENCES

  • 1 Quality Standards Subcommittee of the American Academy of Neurology . Practice parameter: management issues for women with epilepsy.  Neurology. 1998;  51 944-948
    PubMedGoogle Scholar
  • 2 Seale C G, Morrell M J, Nelson L, Druzin M L. Analysis of prenatal and gestational care given to women with epilepsy.  Neurology. 1998;  51 1039-1045
    PubMedGoogle Scholar
  • 3 Morrell M J, Sarto G E, Shafer P O, Borda E A, Herzog A, Callanan M. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers.  J Womens Health Gend Based Med. 2000;  9 959-965
    CrossrefPubMedGoogle Scholar
  • 4 Long L, Mantouris G. Knowledge of women's issues and epilepsy (KOWIE-II), a survey of healthcare professionals.  Epilepsy Behav. 2005;  6 90-93
    CrossrefPubMedGoogle Scholar
  • 5 Klein P, van Passel-Clark L M, Pezzullo J C. Onset of epilepsy at the time of menarche.  Neurology. 2003;  60 495-497
    PubMedGoogle Scholar
  • 6 Herzog A G, Klein P, Ransil B J. Three patterns of catamenial epilepsy.  Epilepsia. 1997;  38 1082-1088
    PubMedGoogle Scholar
  • 7 Herzog A G, Harden C L, Liporace J et al.. Frequency of catamenial seizure exacerbation in women with localization related epilepsy.  Ann Neurol. 2004;  56 431-434
    CrossrefPubMedGoogle Scholar
  • 8 Scharfman H E, MacLusky N J. The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female.  Epilepsia. 2006;  47 1423-1440
    CrossrefPubMedGoogle Scholar
  • 9 Morrell M J, Giudice L, Flynn K L et al.. Predictors of ovulatory failure in women with epilepsy.  Ann Neurol. 2002;  52 704-711
    CrossrefPubMedGoogle Scholar
  • 10 Lim L L, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy.  Epilepsia. 2001;  42 746-749
    CrossrefPubMedGoogle Scholar
  • 11 Mattson R H, Cramer J A, Caldwell B V, Siconolfi B C. Treatment of seizures with medroxyprogesterone acetate: preliminary report.  Neurology. 1984;  34 1255-1258
    PubMedGoogle Scholar
  • 12 Herzog A G. Progesterone therapy in women with complex partial and secondary generalized seizures.  Neurology. 1995;  45 1660-1662
    PubMedGoogle Scholar
  • 13 Herzog A G. Progesterone therapy in women with epilepsy: a three year follow-up.  Neurology. 1999;  52 1917-1918
    PubMedGoogle Scholar
  • 14 Speidel B D, Meadow S R. Maternal epilepsy and abnormalities of the fetus and newborn.  Lancet. 1972;  2 839-843
    PubMedGoogle Scholar
  • 15 Yerby M S. Management issues for women with epilepsy: neural tube defects and folic acid supplementation.  Neurology. 2003;  61(suppl 2) S23-S26
    PubMedGoogle Scholar
  • 16 Kaneko S, Battino D, Andermann E et al.. Congenital malformations due to antiepileptic drugs.  Epilepsy Res. 1999;  33 145-158
    CrossrefPubMedGoogle Scholar
  • 17 Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in the offspring of women with epilepsy.  Neurology. 2003;  60 575-579
    CrossrefPubMedGoogle Scholar
  • 18 Morrow J, Russell A, Guthrie E et al.. Malformation risk of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
    CrossrefPubMedGoogle Scholar
  • 19 Artama M, Ritvanen A, Gissler M, Isojarvi J, Auvinen A. Congenital structural anomalies in offspring of women with epilepsy: a population based cohort study in Finland.  Int J Epidemiol. 2006;  35 280-287
    PubMedGoogle Scholar
  • 20 Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population based register study.  Acta Paediatr. 2004;  93 174-176
    CrossrefPubMedGoogle Scholar
  • 21 Wyszynski D F, Nambisan M, Surve T et al.. Increased rate of major malformations in offspring exposed to valproate during pregnancy.  Neurology. 2005;  64 961-965
    CrossrefPubMedGoogle Scholar
  • 22 Vajda F J, Eadie M J. Maternal valproate dosage and fetal malformations.  Acta Neurol Scand. 2005;  112 137-143
    CrossrefPubMedGoogle Scholar
  • 23 Vajda F J, Hitchcock A, Graham J et al.. Fetal malformations and seizure control: 52 months of data of the Australian Pregnancy Registry.  Eur J Neurol. 2006;  13 645-654
    CrossrefPubMedGoogle Scholar
  • 24 Adab N, Kini U, Vinten J et al.. The longer term outcome of children born to mothers with epilepsy.  J Neurol Neurosurg Psychiatry. 2004;  75 1575-1583
    CrossrefPubMedGoogle Scholar
  • 25 Holmes L B, Wyszynski D R, Baldwin E J, Haebecker E, Glassman L H, Smith C R. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract].  Birth Defects Res Part A Clin Mol Teratol. 2006;  76 318
    PubMedGoogle Scholar
  • 26 Samren E B, van Duijn C M, Kock S et al.. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.  Epilepsia. 1997;  38 981-990
    PubMedGoogle Scholar
  • 27 Yerby M S, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy.  Cleve Clin J Med. 2004;  71(suppl 2) S25-S37
    PubMedGoogle Scholar
  • 28 EURAP Investigators . Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry.  Neurology. 2006;  66 354-360
    CrossrefPubMedGoogle Scholar
  • 29 Teramo K, Hiilesmaa V K. Pregnancy and fetal complications in epileptic pregnancies: review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D Epilepsy, Pregnancy and the Child. New York; Raven Press 1982: 53-59
    Google Scholar
  • 30 Teramo K, Hiilesmaa V, Saarikoski A B. Fetal heart rate during a maternal grand mal epileptic seizure.  J Perinat Med. 1979;  7 3-6
    PubMedGoogle Scholar
  • 31 Nei M, Daly S, Liporace J. A maternal partial complex seizure in labor can affect fetal heart rate.  Neurology. 1998;  51 904-906
    PubMedGoogle Scholar
  • 32 Sahoo S, Klein P. Maternal complex partial seizure associated with fetal distress.  Arch Neurol. 2005;  62 1304-1305
    CrossrefPubMedGoogle Scholar
  • 33 Centers for Disease Control . Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects.  MMWR Recomm Rep. 1992;  41 1-7
    PubMedGoogle Scholar
  • 34 Section of Breastfeeding, American Academy of Pediatrics . Breastfeeding and the use of human milk.  Pediatrics. 2005;  115 496-506
    CrossrefPubMedGoogle Scholar
  • 35 Henshaw S K. Unintended pregnancy in the United States.  Fam Plann Perspect. 1998;  30 24-29
    CrossrefPubMedGoogle Scholar
  • 36 Fairgrieve S D, Jackson M, Jonas P et al.. Population based prospective study of the care of women with epilepsy in pregnancy.  BMJ. 2000;  321 674-675
    PubMedGoogle Scholar
  • 37 Krauss G L, Brandt J, Cambell M, Plate C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologist and obstetricians.  Neurology. 1996;  46 1534-1539
    CrossrefPubMedGoogle Scholar
  • 38 Bensyl D M, Iuliano D A, Carter M, Santelli J, Gilbert B C. Contraceptive use: United States and territories, behavioral risk factor surveillance system, 2002.  MMWR Surveill Summ. 2005;  54 1-72
    PubMedGoogle Scholar
  • 39 O'Brien M D, Guillebaud J. Contraception for women with epilepsy.  Epilepsia. 2006;  47 1419-1422
    CrossrefPubMedGoogle Scholar
  • 40 Thorneycroft I, Klein P, Simon J. The impact of antiepileptic drug therapy on steroidal contraceptive efficacy.  Epilepsy Behav. 2006;  9 31-39
    PubMedGoogle Scholar
  • 41 Harden C L, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives.  Neurology. 2006;  67(suppl 4) S56-S58
    PubMedGoogle Scholar
  • 42 De Souza A, Brechin S, Penney G. The member's enquiry service: frequently asked questions.  J Fam Plann Reprod Health Care. 2004;  30 57-58
    CrossrefPubMedGoogle Scholar
  • 43 Bounds W, Guillebaud J. Observational series on women using contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs.  J Fam Plann Reprod Health Care. 2002;  28 78-80
    CrossrefPubMedGoogle Scholar
  • 44 Dirubbo N E. Counsel your patients about contraceptive options.  Nurse Pract. 2006;  31 40-44
    CrossrefPubMedGoogle Scholar
  • 45 Sabers A, Ohman I, Christensens J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels.  Neurology. 2003;  61 570-571
    CrossrefPubMedGoogle Scholar
  • 46 Klein P, Serje A, Pezzullo J C. Premature ovarian failure in women with epilepsy.  Epilepsia. 2001;  42 1584-1589
    CrossrefPubMedGoogle Scholar
  • 47 Harden C L, Koppel B S, Herzog A G et al.. Seizure frequency is associated with age at menopause in women with epilepsy.  Neurology. 2003;  61 451-455
    PubMedGoogle Scholar
  • 48 Harden C L, Pulver M C, Ravdin L, Jacobs A R. The effect of menopause and perimenopause on the course of epilepsy.  Epilepsia. 1999;  40 1402-1407
    PubMedGoogle Scholar
  • 49 Abbasi F, Krumholz A, Kittner S J, Langenberg P. Effects of menopause on seizures in women with epilepsy.  Epilepsia. 1999;  40 205-210
    PubMedGoogle Scholar
  • 50 Hulley S, Grady D, Bush T et al.. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.  JAMA. 1998;  280 605-613
    CrossrefPubMedGoogle Scholar
  • 51 Rossouw J E, Anderson G L, Prentice R L et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
    CrossrefPubMedGoogle Scholar
  • 52 Harden C L, Herzog A G, Nikolov B G et al.. Hormone replacement therapy in women with epilepsy: a randomized double-blind placebo-controlled study.  Epilepsia. 2006;  47 1447-1451
    CrossrefPubMedGoogle Scholar
  • 53 U.S. Department of Health and Human Services .Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD; U.S. Department of Health and Human Services, Public Health Service, Office of Surgeon General 2004
    Google Scholar
  • 54 Empana J P, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study.  J Am Geriatr Soc. 2004;  52 685-690
    CrossrefPubMedGoogle Scholar
  • 55 Valmadrid C, Voorhees C, Litte B, Schneyer C. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy.  Arch Neurol. 2001;  58 1369-1374
    CrossrefPubMedGoogle Scholar
  • 56 Cummings S R, Nevitt M C, Browner W S et al.. Risk factors for hip fracture in white women.  N Engl J Med. 1995;  332 767-773
    CrossrefPubMedGoogle Scholar
  • 57 Van Staa T P, Leufkens H G, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women.  Bone. 2002;  31 508-514
    CrossrefPubMedGoogle Scholar
  • 58 Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy.  Acta Neurol Scand. 1999;  99 269-275
    CrossrefPubMedGoogle Scholar
  • 59 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs.  Epilepsia. 2004;  45 1330-1337
    CrossrefPubMedGoogle Scholar
  • 60 Souverein P C, Webb D J, Petri H, Weil J, Van Staa T P, Egberts T. Incidence of fractures among epilepsy patients: a population-based prospective cohort study in the General Practice Research Database.  Epilepsia. 2005;  46 304-310
    CrossrefPubMedGoogle Scholar
  • 61 Petty S J, Paton L M, O'Brien T J et al.. Effect of antiepileptic medication on bone mineral measures.  Neurology. 2005;  65 1358-1363
    CrossrefPubMedGoogle Scholar
  • 62 Pack A M, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs.  Cleve Clin J Med. 2004;  71(suppl 2) S42-S48
    PubMedGoogle Scholar
  • 63 Valimaki M J, Tiihonen M, Laitinen K et al.. Bone mineral density measured by dual energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.  J Bone Miner Res. 1994;  9 631-637
    PubMedGoogle Scholar
  • 64 Ensrud K E, Walzak T S, Blackwell T, Ensrued E R, Bowman P J, Stone K L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study.  Neurology. 2004;  62 2051-2057
    PubMedGoogle Scholar
  • 65 Pack A M, Morrell M J, Marcus R et al.. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.  Ann Neurol. 2005;  57 252-257
    CrossrefPubMedGoogle Scholar
  • 66 Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal and postpubertal patients receiving carbamazepine.  Epilepsia. 2002;  43 1488-1492
    CrossrefPubMedGoogle Scholar
  • 67 Sheth R D, Wesolowski C A, Jacob J C et al.. Effect of carbamazepine and valproate on bone mineral density.  J Pediatr. 1995;  127 256-262
    PubMedGoogle Scholar
  • 68 Mintzer S, Bopana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.  Epilepsia. 2006;  47 510-515
    CrossrefPubMedGoogle Scholar
  • 69 Sato Y, Kondo I, Ishida S et al.. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy.  Neurology. 2001;  57 445-449
    CrossrefPubMedGoogle Scholar
  • 70 Boluk A, Guzelipek M, Savli H, Temel I, Ozisik H I, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients.  Pharmacol Res. 2004;  50 93-97
    CrossrefPubMedGoogle Scholar
  • 71 Burke M S. Current roles and realities of noninvasive assessment of osteoporosis.  Curr Opin Endocrinol Diabetes. 2004;  11 330-337
    CrossrefPubMedGoogle Scholar
  • 72 Pack A M, Olarte L S, Morrell M J, Flaster E, Resor S R, Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs.  Epilepsy Behav. 2003;  4 169-174
    CrossrefPubMedGoogle Scholar
  • 73 Farhat G, Yamout B, Mikati A, Demirjian S, Sawaya R, Fuleihan G E. Effect of antiepileptic drugs on bone density in ambulatory patients.  Neurology. 2002;  58 1348-1353
    CrossrefPubMedGoogle Scholar
  • 74 Binkley N, Bilezikian J P, Kendler D L et al.. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference.  J Clin Densitom. 2006;  9 4-14
    CrossrefPubMedGoogle Scholar
  • 75 Harden C L. Menopause and bone density issues for women with epilepsy.  Neurology. 2003;  61(suppl 2) S16-S22
    PubMedGoogle Scholar
  • 76 Mikati M A, Dib L, Yamout B, Sawaya R, Rahi A C, Fuleihan G E. Two randomized vitamin D trials in ambulatory patients on anticonvulsants.  Neurology. 2006;  67 2005-2014
    CrossrefPubMedGoogle Scholar
  • 77 Drezner M K. Treatment of anticonvulsant drug-induced bone disease.  Epilepsy Behav. 2004;  5 S41-S47
    CrossrefPubMedGoogle Scholar

Katherine H NoeM.D Ph.D. 

Department of Neurology

5 East, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054